rezvilutamide   Click here for help

GtoPdb Ligand ID: 12798

Synonyms: Ariane® | example 44 [WO2014036897A1] | SHR-3680 | SHR3680
Approved drug
rezvilutamide is an approved drug (China NMPA (2022))
Compound class: Synthetic organic
Comment: Rezvilutamide is an oral, nonsteroidal androgen receptor antagonist [3].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 129.12
Molecular weight 479.47
XLogP 1.41
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC1(C)C(=O)N(C2=CC=C(C#N)C(=C2)C(F)(F)F)C(=S)N1C3=CC=C(C=C3)OC[C@H](CO)O
Isomeric SMILES CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)OC[C@H](CO)O)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChI InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1
InChI Key KRBMOYIWQCZVHA-INIZCTEOSA-N
References
1. Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J et al.. (2022)
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Lancet Oncol, 23 (10): 1249-1260. [PMID:36075260]
2. Keam SJ. (2023)
Rezvilutamide: First Approval.
Drugs, 83 (2): 189-193. [PMID:36630077]
3. Lu H, Sun P, Fei H, Jiang H, Wang H, Dong Q. (2014)
Imidazoline derivatives, preparation methods thereof, and their applications in medicine.
Patent number: WO2014036897A1. Assignee: Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd. Priority date: 26/08/2013. Publication date: 13/03/2014.
4. Qin X, Ji D, Gu W, Han W, Luo H, Du C, Zou Q, Sun Z, He C, Zhu S et al.. (2022)
Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.
BMC Med, 20 (1): 84. [PMID:35241087]